ATE371653T1 - Benzoxazinderivate und deren verwendungen - Google Patents

Benzoxazinderivate und deren verwendungen

Info

Publication number
ATE371653T1
ATE371653T1 AT04820410T AT04820410T ATE371653T1 AT E371653 T1 ATE371653 T1 AT E371653T1 AT 04820410 T AT04820410 T AT 04820410T AT 04820410 T AT04820410 T AT 04820410T AT E371653 T1 ATE371653 T1 AT E371653T1
Authority
AT
Austria
Prior art keywords
benzoxazine derivatives
benzoxazine
derivatives
Prior art date
Application number
AT04820410T
Other languages
English (en)
Inventor
Jacob Berger
Robin Clark
Shu-Hai Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE371653T1 publication Critical patent/ATE371653T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04820410T 2003-12-09 2004-11-30 Benzoxazinderivate und deren verwendungen ATE371653T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52837803P 2003-12-09 2003-12-09

Publications (1)

Publication Number Publication Date
ATE371653T1 true ATE371653T1 (de) 2007-09-15

Family

ID=34699863

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04820410T ATE371653T1 (de) 2003-12-09 2004-11-30 Benzoxazinderivate und deren verwendungen

Country Status (21)

Country Link
US (1) US7202241B2 (de)
EP (1) EP1694656B1 (de)
JP (1) JP4527730B2 (de)
KR (1) KR100827915B1 (de)
CN (1) CN100532369C (de)
AR (1) AR046753A1 (de)
AT (1) ATE371653T1 (de)
AU (1) AU2004299201B2 (de)
BR (1) BRPI0416873A (de)
CA (1) CA2547764A1 (de)
CO (1) CO5700768A2 (de)
DE (1) DE602004008668T2 (de)
ES (1) ES2291984T3 (de)
IL (1) IL175817A0 (de)
MY (1) MY145576A (de)
NO (1) NO20062491L (de)
NZ (1) NZ547120A (de)
RU (1) RU2354651C2 (de)
TW (1) TW200522953A (de)
WO (1) WO2005058847A1 (de)
ZA (1) ZA200604725B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1408976T5 (da) * 2001-07-20 2011-01-10 Psychogenics Inc Behandling af ADHD (Attention deficit hyperactivity disorder)
ES2359725T3 (es) * 2004-09-30 2011-05-26 F. Hoffmann-La Roche Ag Composiciones y métodos para el tratamiento de trastornos cognitivos.
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
WO2007108742A1 (en) * 2006-03-17 2007-09-27 Astrazeneca Ab Novel tetralins as 5-ht6 modulators
CL2007003044A1 (es) * 2006-10-24 2008-07-04 Wyeth Corp Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros.
WO2011023753A1 (en) * 2009-08-27 2011-03-03 Glaxo Group Limited Benzoxazine derivatives as glycine transport inhibitors
CN101836993B (zh) 2010-05-20 2011-06-22 山东大学 2，3-二氢-3-羟甲基-6-氨基-[1，4]-苯并噁嗪在制备诱导胚胎干细胞向血管内皮细胞分化药物中的应用
CN102060810B (zh) * 2010-12-20 2012-07-04 金坛市爱特生物科技有限公司 一种n-叔丁氧羰基-哌嗪的提纯方法
MX2016010998A (es) 2014-02-27 2017-03-31 Lycera Corp Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
CA2953004C (en) 2014-07-08 2023-02-21 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
CA2982847A1 (en) 2015-05-05 2016-11-10 Lycera Corporation Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
HK1253734A1 (zh) 2015-06-11 2019-06-28 The Regents Of The University Of Michigan 用作RORγ激动剂和用於治疗疾病的芳基二氢-2H-苯并[B][1，4]恶嗪磺酰胺和相关化合物
CN109568321B (zh) * 2019-01-14 2022-02-22 山东轩竹医药科技有限公司 RORγ调节剂
TW202220958A (zh) * 2020-08-07 2022-06-01 美商卡司馬療法公司 Ｔｒｐｍｌ調節劑

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8803419D0 (en) * 1988-02-15 1988-03-16 Erba Carlo Spa 1 4-benzoxazine & 1 4-benzothiazine derivatives & process for their preparation
GB9507203D0 (en) 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
AU732863B2 (en) 1997-04-18 2001-05-03 Smithkline Beecham Plc Indole derivatives having combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity
EP1175412A1 (de) * 1999-04-28 2002-01-30 Dr. Reddy's Research Foundation Substituierte bicyclische heterocycle, verfahren zu ihrer herstellung und ihre verwendung als mittel gegen fettsucht und cholesterol
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
WO2001057003A1 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa
KR100636475B1 (ko) * 2002-05-13 2006-10-18 에프. 호프만-라 로슈 아게 5-ｈｔ6 조절제로서 벤족사진 유도체 및 이의 용도
PT1562918E (pt) * 2002-11-08 2008-03-12 Hoffmann La Roche Benzoxazinonas substituídas e as suas utilizações

Also Published As

Publication number Publication date
EP1694656A1 (de) 2006-08-30
EP1694656B1 (de) 2007-08-29
NO20062491L (no) 2006-09-06
ZA200604725B (en) 2007-12-27
MY145576A (en) 2012-02-29
KR20060097758A (ko) 2006-09-15
CA2547764A1 (en) 2005-06-30
DE602004008668T2 (de) 2008-06-12
US20050124613A1 (en) 2005-06-09
ES2291984T3 (es) 2008-03-01
RU2006124513A (ru) 2008-01-27
KR100827915B1 (ko) 2008-05-07
AR046753A1 (es) 2005-12-21
CN1890227A (zh) 2007-01-03
CO5700768A2 (es) 2006-11-30
CN100532369C (zh) 2009-08-26
WO2005058847A1 (en) 2005-06-30
TW200522953A (en) 2005-07-16
BRPI0416873A (pt) 2007-02-27
JP2007513904A (ja) 2007-05-31
DE602004008668D1 (de) 2007-10-11
JP4527730B2 (ja) 2010-08-18
IL175817A0 (en) 2006-10-05
US7202241B2 (en) 2007-04-10
NZ547120A (en) 2009-02-28
AU2004299201A1 (en) 2005-06-30
RU2354651C2 (ru) 2009-05-10
AU2004299201B2 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
DE602004019294D1 (de) Tetrahydronaphthalin- und harnstoffderivate
DE60326611D1 (de) N und dergleichen
DE602005013491D1 (de) Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel
MA29039B1 (fr) Dibenzylamines et derives
DE60332957D1 (de) Immunoglobulinvarianten und deren verwendungen
DK1633365T3 (da) Makrocykliske quinazolinderivater som antiproliferative midler
DE602004020474D1 (de) Vegf-traps und deren therapeutische anwendungen
DE60308998D1 (de) N-aryl-2-oxazolidinon-5-carbonsäureamide und deren derivate und deren verwendung als antibakterielle mittel
ATE316523T1 (de) Benzoxazinderivate als 5-ht6-modulatoren und deren verwendungen
DE60334438D1 (de) Zünder und Trockner damit
ATE371653T1 (de) Benzoxazinderivate und deren verwendungen
DE602004021477D1 (de) Kondensierte heterocyclen und deren verwendungen
ATE512148T1 (de) Pyrazolo- und imidazopyrimidinderivate
ATE423117T1 (de) Heterocyclische 7-aminoalkylidenylchinolone und - naphthyridone
NO20054135D0 (no) Kipolinon/benzoksazin derivater og anvendelser derav
ATE455755T1 (de) Tetralin- und indanderivate und deren anwendungen
DE50206476D1 (de) Cyanoanthranylamid-derivate und deren verwendung als arzneimittel
DE10338270B4 (de) Variator und Variatoranordnung
ATE420081T1 (de) Trifluormethylbenzamidderivate und therapeutische verwendungen dafür
DE602005007866D1 (de) 1-phenyl- und 1-pyridylpyrazolderivate und deren verwendung als pestizide
DE602005017283D1 (de) Ausgewählte kondensierte heterocyclen und deren anwendung
DE602004004737D1 (de) Airbag und Airbaganordnung
EP1687398A4 (de) Hiv-abhängige expressionskonstrukte und verwendungen dafür
ATE477248T1 (de) Benzoxazin- und chinoxalinderivate und anwendungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1694656

Country of ref document: EP